Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 5,401 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 5,401 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the sale, the director now directly owns 443,885 shares of the company’s stock, valued at approximately $6,107,857.60. This trade represents a 1.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Tyra Biosciences Price Performance

TYRA stock opened at $12.67 on Friday. Tyra Biosciences, Inc. has a 1 year low of $12.60 and a 1 year high of $29.60. The firm has a 50-day moving average of $15.11 and a 200 day moving average of $18.81.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). On average, sell-side analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors have recently added to or reduced their stakes in TYRA. Alta Partners Management Company L.P. bought a new stake in shares of Tyra Biosciences during the 4th quarter valued at $56,716,000. Janus Henderson Group PLC bought a new position in shares of Tyra Biosciences in the 3rd quarter worth about $24,994,000. Walleye Capital LLC lifted its position in Tyra Biosciences by 306.5% during the 3rd quarter. Walleye Capital LLC now owns 126,597 shares of the company’s stock valued at $2,976,000 after acquiring an additional 95,451 shares during the period. Polar Asset Management Partners Inc. bought a new stake in Tyra Biosciences during the third quarter worth about $2,071,000. Finally, Raymond James Financial Inc. purchased a new stake in Tyra Biosciences in the fourth quarter worth about $761,000. Institutional investors own 84.14% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on TYRA shares. Wedbush reiterated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research report on Friday, October 25th. UBS Group initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target for the company. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Monday, January 13th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $30.50.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.